GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rezorstobart   Click here for help

GtoPdb Ligand ID: 14521

Immunopharmacology Ligand
Compound class: Antibody
Comment: Rezorstobart (IMT-009; Immunitas Therapeutics) is an anti-CD161 (KLRB1) monoclonal antibody. It is designed to prevent receptor interaction with its ligand C-type lectin domain family 2 member D, to disinhibit natural killer cells and promote a T cell-mediated anti-tumour response. Peptide sequences for the heavy and light chains of rezorstobart are claimed as consensus sequences of Ab9 in Immunitas Therapeutics' patent US12215159 [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Białoszewska A, Olkowska-Truchanowicz J, Bocian K, Osiecka-Iwan A, Czop A, Kieda C, Malejczyk J. (2018)
A Role of NKR-P1A (CD161) and Lectin-like Transcript 1 in Natural Cytotoxicity against Human Articular Chondrocytes.
J Immunol, 200 (2): 715-724. [PMID:29212911]
2. Bialoszewska A, Malejczyk J. (2018)
Biological and Clinical Significance of Human NKRP1A/LLT1 Receptor/Ligand Interactions.
Crit Rev Immunol, 38 (6): 479-489. [PMID:31002602]
3. Kyrysyuk O, Wucherpfennig KW. (2023)
Designing Cancer Immunotherapies That Engage T Cells and NK Cells.
Annu Rev Immunol, 41: 17-38. [PMID:36446137]
4. Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, Mathew PA. (2018)
Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
Am J Cancer Res, 8 (6): 1050-1063. [PMID:30034942]
5. Tisdale A, Bialucha U, Punkosdy G, Fusco A, Irvine F, Rosentrater E, Scanlon E, Battles M. (2025)
Anti-CD161 antibodies and uses thereof.
Patent number: US12215159B2. Assignee: Immunitas Therapeutics Inc, Adimab LLC. Priority date: 21/02/2024. Publication date: 04/02/2025.